The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma, A Multicenter, Prospective Blinded Pivotal Study
Any male or female patient diagnosed with incident or recurrent Urothelial Cell Carcinoma and undergoing surveillance at 3 month intervals.
Has had all urothelial cell carcinoma tumor resected within the past 12 months
Has a plan for cystoscopic surveillance (adjuvant intravesical therapy allowed)
Able to provide legally effective informed consent
Able to produce 45mL of urine
Other eligibility criteria may apply.
Planning to undergo radical cystectomy or chemotherapy-radiation for Urothelial Cell Carcinoma
Other exclusion criteria may apply.